We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Maternal Lipid Profile Tied to Pediatric CHD Risk

By LabMedica International staff writers
Posted on 25 Sep 2021
Congenital heart disease (CHD among live births, is the major form of birth defect and the leading cause of childhood mortality with an incidence of 9.1‰. More...
The occurrence of CHD is caused by many factors.

With the improvement in living standards and an increasing number of women with advanced maternal age, there is an increase in the prevalence of chronic metabolic diseases, such as obesity, diabetes, hypertension, and hyperlipidemia, among pregnant women.

Clinical Scientists at the Children's Hospital of Fudan University (Shanghai, China) carried out a single-center case–control study that included 230 mothers of offspring with CHD and 381 without CHD. Maternal lipid levels were determined on fasting blood samples taken in the first trimester. Relevant demographic and clinical data were extracted from the medical records. Maternal lipid profile was compared between the two groups, and regression analysis was performed to evaluate the association between lipid profile and CHD risk in offspring.

Fasting peripheral blood samples were collected between eight and 14 weeks of gestation. Folic acid, vitamin B12, thyroid abnormality, homocysteine (Hcy), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), free fatty acid, Apolipoprotein-A1 (Apo-A1), Apolipoprotein-B (Apo-B), fasting blood glucose, and hemoglobin A1c (HbA1c) were all measured. TG, TC, HDL-C, LDL-C, free fatty acid, Apo-A1, Apo-B, and fasting blood glucose were analyzed by an automatic biochemical analyzer (Hitachi 7180, Tokyo, Japan) using commercially available kits. Folic acid and vitamin B12 were measured using the Architect i2000chemiluminescence immunoassay analyzer (Abbott, Lake Forest, IL, USA). Serum Hcy measurements were carried out by Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC/MS/MS) using an API 3000 LC/MS/MS system (Applied Biosystems, Waltham, MA, USA).

The investigators reported that compared with the control group, levels of triglyceride, apolipoprotein-A1, and apolipoprotein-B in early pregnancy were significantly higher in the CHD group. Multivariate analyses showed that triglyceride (odds ratio [OR] 2.46), total/high-density lipoprotein cholesterol (OR 2.10), and apolipoprotein-A1 (OR 2.73), were positively associated with CHD risk in offspring. Each lipid biomarker was associated with an almost twofold increased risk of CHD, independent of HbA1c and Hcy.

The authors concluded that mild dyslipidemia in early pregnancy was closely associated with the occurrence of CHD in offspring. In combination with previous studies, it is possible that lipid metabolism in early pregnancy may influence the outcome of pregnancy. The study was published on August 3,2021 in the journal Acta Obstetricia et Gynecologica Scandinavica.

Related Links:

Children's Hospital of Fudan University
Hitachi 
Abbott
Applied Biosystems


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.